← All trials
NCT06186401
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Jan 2, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 20
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of California, San FranciscoSponsor investigator
- California Institute for Regenerative Medicine (CIRM)Collaborator
- University of California, San FranciscoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.